Related Experiment Videos
Imaging amyloid-beta deposits in vivo
Brian J Bacskai1, William E Klunk, Chester A Mathis
1Alzheimer Research Unit, Massachusetts General Hospital, Charlestown 02129, USA.
Summary
Diagnosing Alzheimer disease (AD) in living patients is challenging. This review explores advanced imaging techniques for detecting amyloid-beta plaques and neurofibrillary tangles in the brain, aiding therapeutic development.
Area of Science:
- Neurology
- Medical Imaging
- Biochemistry
Background:
- Alzheimer disease (AD) diagnosis is definitive only postmortem.
- Key neuropathologic hallmarks include neuronal loss, neurofibrillary tangles (NFTs), and amyloid-beta plaques.
- In vivo detection of these hallmarks is crucial for therapeutic evaluation.
Purpose of the Study:
- To review current techniques for in vivo imaging of amyloid-beta deposits in the brain.
- To discuss the development of imaging agents targeting amyloid-beta.
- To highlight challenges and progress in non-invasive AD diagnostics.
Main Methods:
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET)
- Single photon emission computed tomography (SPECT)
- Multiphoton microscopy
Main Results:
- Various imaging modalities can detect amyloid-beta deposits.
- Specific imaging agents targeting amyloid-beta have been developed.
- Challenges include crossing the blood-brain barrier and achieving high sensitivity/specificity.
Conclusions:
- In vivo imaging of amyloid-beta plaques is advancing.
- Development of effective imaging agents is critical for AD research and treatment.
- Improved imaging will facilitate the assessment of novel AD therapeutics.